Anavex Life Sciences Corp Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.11 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.02Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $187.2M Enterprise Value $68.9M Shares Outstanding 91.5M diluted Next Earnings Date24 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Anavex Life Sciences is undergoing a critical transition period marked by regulatory setbacks, leadership changes, and compliance challenges. While the company maintains a robust cash runway of over three years with zero debt, the withdrawal of its EU marketing authorization application for blarcamesine and the sudden departure of its long-standing CEO, Christopher Missling, have introduced significant near-term uncertainty. The appointment of Terrie Kellmeyer as Interim CEO brings strong clinical and regulatory expertise, but the delayed filing of its Form 10-Q has triggered a Nasdaq delinquency notice. Investors should remain on the sidelines until there is clearer regulatory alignment with the FDA and EMA, and the company resolves its financial reporting delays. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$20.00 Mean target$20.00 High · most bullish analyst$20.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.5020% The bear case is triggered if the EMA upholds its negative opinion on blarcamesine, the FDA requires an expensive and lengthy new Phase 3 trial, or the company fails to regain Nasdaq compliance, leading to delisting. Continued leadership instability and class-action litigation could further depress valuation, forcing the company to burn through its cash reserves without commercializing its pipeline. Base CaseCentral scenario $5.0055% The base case assumes that Anavex successfully submits its compliance plan to Nasdaq, files its delayed Form 10-Q, and avoids delisting. Clinical development continues at a measured pace, but regulatory approvals in both the U.S. and Europe are pushed back, with profitability delayed until 2027 or 2028. The stock is expected to trade in a volatile range reflecting ongoing clinical trial progress and regulatory dialogue. Bull CaseUpside scenario $20.0025% The bull case relies on the successful re-examination of blarcamesine by the EMA or a clear, accelerated pathway to an NDA agreed upon with the FDA. If the newly appointed Interim CEO can leverage her regulatory track record to secure approvals, blarcamesine's oral administration and lack of ARIA (brain swelling/bleeding) side effects could position it as a highly competitive, scalable alternative to existing amyloid-targeting infusions. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |